BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 1347763)

  • 1. Xamoterol in severe congestive heart failure: long-term oral treatment, a double-blind randomised study.
    Tangø M; Lyngborg K; Mehlsen J; Svendsen TL; Trap-Jensen J
    Int J Cardiol; 1992 Jan; 34(1):63-8. PubMed ID: 1347763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute and chronic hemodynamic effects of xamoterol in mild to moderate congestive heart failure.
    Virk SJ; Qiang FX; Anfilogoff NH; Murray RG; Littler WA; Davies MK
    Am J Cardiol; 1991 May; 67(12):48C-52C; discussion 52C-54C. PubMed ID: 1673587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of xamoterol on resting and exercise haemodynamics in patients with chronic heart failure.
    Virk SJ; Davies MK
    Br J Clin Pharmacol; 1989; 28 Suppl 1(Suppl 1):15S-22S. PubMed ID: 2572250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Xamoterol in severe heart failure. The Xamoterol in Severe Heart Failure Study Group.
    Lancet; 1990 Jul; 336(8706):1-6. PubMed ID: 1694945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy and safety of chronic oral administration of xamoterol to patients with severe heart failure treated with ACE inhibitors.
    Pouleur H; Hanet C; Rousseau MF
    Br J Clin Pharmacol; 1989; 28 Suppl 1(Suppl 1):82S-83S. PubMed ID: 2572263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical experience of therapy with xamoterol in patients with severe systolic and diastolic dysfunction.
    Pouleur H; Hanet C; Rousseau MF
    Eur Heart J; 1990 Apr; 11 Suppl A():33-8. PubMed ID: 1971587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Double-blind placebo-controlled comparison of digoxin and xamoterol in chronic heart failure. The German and Austrian Xamoterol Study Group.
    Lancet; 1988 Mar; 1(8584):489-93. PubMed ID: 2893916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Digoxin and xamoterol in patients with moderate chronic heart failure. A double-blind, randomized, controlled study.
    Sorensen EV; Sterndorff B; Andersen MF; Faergeman O
    Cardiovasc Drugs Ther; 1989 Apr; 3(2):203-9. PubMed ID: 2577283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Role of adrenergic beta receptor partial agonists in left ventricular failure of ischemic origin. Value of xamoterol (ICI 118,587, Corwin)].
    Rousseau MF; Cheron P; Nannan M; Vincent MF; Lavenne F; Pouleur H
    Ann Med Interne (Paris); 1985; 136(3):247-50. PubMed ID: 2862823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The acute effects of intravenous xamoterol ('Corwin', I.C.I. 118, 587) on resting and exercise haemodynamics in patients with mild to moderate heart failure.
    Virk SJ; Anfilogoff NH; Lawson N; Sadler AM; Smith SJ; Nuttall A; Murray RG; Littler WA; Davies MK
    Eur Heart J; 1989 Mar; 10(3):227-34. PubMed ID: 2565233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of tolerance development after long-term administration of the partial beta-adrenoceptor agonist xamoterol.
    Erlemeier HH; Kupper W; Bleifeld W
    Cardiology; 1990; 77(1):30-9. PubMed ID: 1972349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beta, partial agonists to treat heart failure: effects of xamoterol upon cardiac function and clinical status.
    Heng MK
    Clin Cardiol; 1990 Mar; 13(3):171-6. PubMed ID: 1969783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ischaemic left ventricular failure: evidence of sustained benefit after 18 months' treatment with xamoterol.
    Vigholt-Sørensen E; Faergeman O
    Br Heart J; 1990 Sep; 64(3):186-9. PubMed ID: 1976339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exercise capacity, arrhythmias, humoral and chemical parameters during long-term therapy with xamoterol.
    Erlemeier HH; Kupper W; Bleifeld W
    Int J Cardiol; 1990 Aug; 28(2):197-208. PubMed ID: 1697569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of xamoterol, a beta 1 adrenoceptor partial agonist, in patients with ischaemic dysfunction of the left ventricle.
    Vigholt-Sørensen E; Faergeman O; Snow HM
    Br Heart J; 1989 Nov; 62(5):335-41. PubMed ID: 2574049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Xamoterol, a beta 1-adrenoceptor partial agonist: review of the clinical efficacy in heart failure.
    Marlow HF
    Br J Clin Pharmacol; 1989; 28 Suppl 1(Suppl 1):23S-30S. PubMed ID: 2572251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of the partial beta 1-agonist xamoterol on heart rate and ventricular arrhythmias in patients with mild to moderate heart failure.
    Virk SJ; Anfilogoff NH; Lawson N; Qiang F; Murray RG; Littler WA; Davies MK
    Eur Heart J; 1990 Oct; 11(10):876-84. PubMed ID: 1979946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The value of xamoterol in moderate ischemic cardiac insufficiency].
    Rousseau MF; Cheron P; Vincent MF; Pouleur H; Lavenne F
    Ann Cardiol Angeiol (Paris); 1984; 33(4):215-8. PubMed ID: 6147115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term efficacy of xamoterol (a beta 1-adrenoceptor partial agonist) in patients with mild to moderate heart failure.
    Sørensen EV; Faergeman O; Day MA; Snow HM
    Br J Clin Pharmacol; 1989; 28 Suppl 1(Suppl 1):86S-88S. PubMed ID: 2572265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvement of left ventricular contractility and relaxation with the beta 1-adrenergic receptor partial agonist xamoterol at rest and during exercise in patients with postinfarction left ventricular dysfunction. A placebo-controlled randomized trial.
    de Feyter PJ; Serruys PW; Suryapranata H
    Circulation; 1990 Feb; 81(2 Suppl):III99-106. PubMed ID: 1967562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.